Paul E. Marik

By April 2022, Marik had become associated with a right-wing political group called Defeat the Mandates. Appearing at a rally in Maryland, Marik began promoting further COVID-19 misinformation, saying without evidence that vaccines, masks and social distancing "didn't work" and that information about "early treatment" had been suppressed – "They don't want you to know this because they want you to be scared".

In March 2021, Marik was reprimanded by the Virginia Board of Medicine and ordered to complete additional education in prescribing practices after it was found he had prescribed drugs, including phenobarbital, oxycodone, tramadol, alprazolam, and diazepam, to people who were not his patients. In November 2021, he sued his employer, Sentara Health, over its ban on prescribing ivermectin for COVID-19. His clinical privileges at Sentara Norfolk General Hospital were suspended shortly afterward. He resigned from Eastern Virginia Medical School effective December 31, 2021.

Marik's findings received attention on social media and National Public Radio, but drew criticism from the wider medical community for being science by press conference. ER doctor Jeremy Faust was one of a number of skeptics of the results, noting the low reliability of the study design and potential for bias. The controversy prompted other groups to conduct studies of the HAT protocol. A systematic review of six randomized and five non-randomized controlled trials in 2021 found that the claimed benefits of the protocol could not be confirmed.

Marik was lead author of a journal article on the efficacy of ivermectin as a COVID-19 treatment, which had been provisionally accepted for publication by a Frontiers Media journal in early 2021, but which was subsequently rejected on account of what the publisher said were "a series of strong, unsupported claims based on studies with insufficient statistical significance" meaning that the article did "not offer an objective [or] balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19".

In November 2021, the Journal of Intensive Care Medicine retracted a paper written by Marik and others associated with the FLCCC, including Pierre Kory. The paper promoted a combination of vitamins and drugs as treatment for patients hospitalized for COVID-19. The combination was called MATH+ by the FLCCC and included methylprednisolone, ascorbic acid, thiamine, heparin, and other ingredients. The retraction was triggered when it was found the paper misreported the mortality figures of hospitalized patients treated with MATH+, falsely making it appear to be an effective treatment.

Marik is a co-founder of the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of physicians and former journalists formed in April 2020 that advocates for ineffective COVID-19 treatments, including hydroxychloroquine, the anti-parasitic drug ivermectin, and intravenous vitamin C.

In 2017, Marik won the American College of Physicians award for outstanding educator of residents and fellows. He has written over 450 peer-reviewed journal articles.

Marik is inventor of the "Marik protocol", also known as the "HAT" protocol, which proposes intravenous administration of hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1) as a treatment for preventing sepsis for people in intensive care. Marik's own initial research, published with four other authors in Chest in 2017, showed a dramatic evidence of benefit. The single-center, observational study compared outcomes of 47 consecutive sepsis patients who were treated with HAT during a 7-month period to 47 consecutive control patients during the preceding 7-month period. The study reported 19 deaths in the control group and 4 deaths in the treatment group.

In 2012, an international committee updated guidelines for the management of severe sepsis and septic shock. In its section of supportive therapy recommendations, the committee based its concept on blood product administrations partly on research performed by Marik and W. Sibbald in 1993.

In 2011, an international committee assembled by the main thoracic and respiratory national societies published guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. The guidelines' section on the treatment of complications relied in part on the results of Marik's 2001 research on the association of gastric reflux and aspiration.

In 2009, Marik became a professor and Chief of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.

In 2005, Marik was named Director at the Division Pulmonary and Critical Care at Jefferson Medical College (JMC) and Thomas Jefferson University Hospital in Philadelphia.

From 2002 to 2006, Marik was part of the Editorial Board of Chest journal.

In 2001, Marik was author of the Handbook of Evidence Based Critical Care. Reviewing its second edition for the journal Anaesthesia and Intensive Care, K. M. Ho wrote in 2011 that the book was "useful for junior doctors or intensive care trainees" but had "some limitations" such as "obvious drug dosage error" and "omissions of hypotensive effects". Another review, by Peter J. Papadakos in 2003 for the journal Respiratory Care, called it "an excellent introduction to the concept of evidence-based medicine".

Marik did a critical care fellowship in London, Ontario, Canada, and subsequently has worked in the United States in teaching hospitals since 1992.

Marik was born in Johannesburg, South Africa. He earned a Master of Medicine in the Specialty of Internal Medicine in 1987 at the University of the Witwatersrand in Johannesburg.

Paul Ellis Marik (born March 26, 1958) is a medical doctor and former professor of medicine who until his resignation in January 2022 served as chair of the Division of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School in Norfolk, Virginia, and was also a critical care doctor at Sentara Norfolk General Hospital. His research interests include sepsis and tissue oxygenation.